Participated · Series B · Dec 2025

D3 Bio focuses on discovering, developing, and registering innovative medicines that address key driver mutations and immune pathways in cancer. Its lead asset is elisrasib (D3S-001), a KRAS G12C inhibitor being advanced toward global Phase III pivotal trials as both a monotherapy and in combination regimens. The company’s broader pipeline spans targeted and immuno-oncology programs built on proprietary clinical insights and biomarker strategies, all of which it owns global rights to. The recent $108 million Series B financing underscores investor confidence in the firm’s scientific approach and global development capabilities. Proceeds will fund late-stage clinical development of elisrasib across the United States, China, and the European Union and support continued pipeline expansion. While specific revenue or patient enrollment figures were not disclosed, the successful raise highlights the company’s solid financial footing for its near-term clinical milestones.

Participated · Series B · Oct 2021

Structure Therapeutics, formerly ShouTi, is a clinical-stage global biopharmaceutical company that leverages structural biology and computational design to discover next-generation small-molecule therapies focused on GPCR targets. Its lead program, GSBR-1290, is an orally available small-molecule GLP‑1 receptor agonist being developed for type 2 diabetes mellitus and obesity. The company completed dosing in a single ascending dose Phase 1 study of GSBR-1290 in 48 healthy volunteers to evaluate safety, tolerability and pharmacokinetics; no serious adverse events were reported. Structure Therapeutics designs biased GLP‑1R agonists intended to mitigate β‑arrestin–mediated internalization and desensitization and to offer a differentiated oral alternative to peptide biologics. Proceeds from the recent financing will be used to advance the lead programs through clinical investigation and to expand application of its structure-based drug discovery platform across GPCR targets. The company announced a corporate name change to Structure Therapeutics to reflect its foundation in structural biology and computational design. ShouTi combines state-of-the-art computational chemistry, structural biology, and large-scale data integration to design orally available medicines with improved pharmaceutical properties. The platform focuses on high-resolution membrane protein structures, particularly GPCRs, to convert biologics and peptide therapeutics into small molecules with enhanced bioavailability and stability. ShouTi is advancing a clinical-stage pipeline targeting chronic cardiovascular, metabolic, and pulmonary diseases. Proceeds from its recent financing will be used to advance the discovery platform and continue development of the clinical-stage programs. The leadership team includes experienced drug developers and pioneers in high-throughput structure-based drug discovery, led by CEO Raymond Stevens. With the Series B, ShouTi has raised $158 million since initiating operations.

Led · Equity · May 2021

MegaRobo Technologies builds automation solutions for life sciences R&D, offering products that range from benchtop workflow automation to fully automated platforms for complex, large-system workflows. Its workflow automation integrates AI software, analytical instruments, hardware and consumables into a single system. The company’s products are adopted in multiple countries and are used in applications such as antibody selection, cell line development and molecular screening. MegaRobo has collaborated with partners including CELLada on high-throughput organoid cultivation and Agilent Technologies on integrated automation for synthetic biology and biopharmaceutical R&D. Led by CEO Daniel Huang, the company plans to continue investing in R&D, increase capacity and pursue global expansion. The article reports a major financing event that strengthens the company’s ability to execute on those plans. MegaRobo is a Chinese high-tech startup that applies artificial intelligence and robotics to life sciences and other sectors. The company describes itself as operating at the intersection of AI, robotics and life‑science applications. According to a company statement reported in the article, MegaRobo has raised $65 million in a funding round. The round was led by Hong Kong‑listed pharma giant WuXi AppTec, and other named participants include Matrix Partners and Sinovation. No operating metrics, valuation, or detailed use-of-proceeds were disclosed in the article. Meiga Robotics builds automated robotics and AI solutions tailored to life‑science applications including new‑drug R&D, gene engineering, and clinical diagnostics. The company has deployed dozens of automated systems and served nearly 100 life‑science customers, driving large efficiency gains: operation precision and repeatability improved by two orders of magnitude, throughput rose up to 100x in some workflows, and certain automated diagnostic workstations enabled daily nucleic‑acid testing capacity of 260,000 samples. Standard product offerings include fully automated reagent filling and dispensing systems (processing up to 900 ep tubes per hour, ~4 seconds per tube). During COVID‑19, Meiga’s automated nucleic‑acid workstations delivered ~20x throughput versus manual methods while reducing frontline infection risk. The company in 2024 launched the Meiga “Kunpeng Laboratory” sub‑brand to integrate robotics, AI and biology, and it has internally developed automated platforms for mammalian cell culture, phenotypic detection, gene editing, and high‑throughput drug screening. Meiga plans to expand its core business and continue R&D and construction of the Kunpeng Laboratory to strengthen its competitive moat in life‑science automation. The company was founded in June 2016 and is based in Beijing.

Participated · Series A · May 2021

Engine Biosciences combines machine learning-enabled network biology and high-throughput combinatorial genetics to discover precision oncology targets, biomarkers, and drug candidates. Its proprietary platforms, NetMAPPR and CombiGEM, integrate proprietary functional genomics, clinical data and AI-enhanced literature mining to map disease networks and validate findings. Engine has identified over thirty previously unidentified precision medicine opportunities and advanced multiple internal programs, including ENB-812, which originated from Engine’s discovery of PKMYT1 as a synthetic lethal target. The company reports biomarkers that can sensitize tumors up to 100-fold to specific investigational drugs and holds an extensive patent portfolio. With teams in Singapore and Silicon Valley, Engine is advancing its pipeline toward the clinic through internal development, collaborations, and partnerships. The new financing is intended to further progress biomarker and target discoveries into clinical translation. Engine Biosciences develops a platform that integrates machine learning, high-throughput biological experimentation, combinatorial genetics, and chemistry to uncover critical gene interactions for drug discovery. Its core technologies are NetMAPPR, a searchable biology platform for predicting gene combinations and targets, and CombiGEM, a combinatorial CRISPR system for experimentally testing hundreds of thousands of gene interactions. Engine uses iterative predict-test-learn cycles to prioritize high-ranking genes and translate findings into drug discovery and chemistry efforts. The company has advanced novel biology findings into proprietary small-molecule inhibitors and a growing pipeline of targeted therapies for genetically defined patient populations in liver, ovarian, colorectal, and breast cancers. Engine plans to expand its precision oncology portfolio, prepare for its first clinical programs, and scale its proprietary technology platform. Financially, the company recently closed a $43M Series A and has raised $53M to date, including a $10M seed round in 2018. Engine Biosciences is advancing a data-driven drug discovery platform that combines massively parallel biological experimentation with artificial intelligence to discover and develop therapies. The company applies its technology across four areas: drug repositioning, new target discovery, precision medicine enablement, and pathway analysis. Engine reports proof of concept across various disease indications and cell types and has active programs in cancer, neurodegeneration, autoimmune, and skin. The company plans to use the seed funding to build its drug discovery platform, expand its scientific and executive teams in Singapore and San Francisco, and pursue preclinical studies internally and with partners. Scientific leadership includes Co-Founder and CEO Jeffrey Lu and scientific founders/academic leaders Timothy Lu, Hu Li, Prashant Mali, and Jim Collins.

Participated · Equity · Feb 2021

Drug Farm leverages proprietary platforms—IDInVivo+ (which integrates genetics and AI to identify and validate targets in living systems) and MedChem5 (used to advance first-in-class candidates)—to discover and progress drug candidates. The company is developing treatments across rare disease, cardiovascular, kidney, metabolic, autoimmune, and infectious disease indications. Its lead program, DF-003, is a first-in-class ALPK1 inhibitor that has shown clinical improvement in an ongoing Phase 1b study for ROSAH syndrome and is positioned to enter a Phase 3 trial; DF-003 has received multiple FDA designations including Fast Track and Orphan Drug. Another key program, DF-006, is an orally administered ALPK1 agonist immunomodulator that completed single and multiple ascending dose evaluations in healthy volunteers and in virologically suppressed HBeAg-negative chronic hepatitis B patients, showing encouraging anti-HBV activity. Drug Farm has entered a clinical collaboration with Xiamen Amoytop Biotech to develop DF-006 for hepatitis B and hepatocellular carcinoma. The recent $55 million Series D first closing provides capital to advance pivotal trials, global development, regulatory activities, and R&D expansion.